Phase 2 trial of oditrasertib in MS patients stopped after goals not met
Sanofi has ended a Phase 2 clinical trial into oditrasertib, anĀ investigational RIPK1 inhibitor therapy, in people with relapsing and progressive multiple sclerosis (MS) after it failed to meet its goals. The study, which had started dosing early last year, failed to show that oditrasertib significantly lowered…